Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR

Fineline Cube Mar 15, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...

Company Deals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline

Fineline Cube Mar 15, 2024

AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...

Company Drug

KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma

Fineline Cube Mar 15, 2024

Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...

Company Deals

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Fineline Cube Mar 15, 2024

Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...

Company Drug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

Fineline Cube Mar 15, 2024

Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...

Company Drug

Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults

Fineline Cube Mar 15, 2024

The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...

Deals Hospital

Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia

Fineline Cube Mar 15, 2024

Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...

Legal / IP

CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...

Drug Legal / IP

CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...

Company

BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries

Fineline Cube Mar 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...

Company

Innovent Biologics Denies Lab Closure, Confirms Relocation to California

Fineline Cube Mar 14, 2024

Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...

Company Deals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

Fineline Cube Mar 14, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...

Company Legal / IP Policy / Regulatory

BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift

Fineline Cube Mar 14, 2024

The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...

Company Drug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

Fineline Cube Mar 14, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...

Company Drug

Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations

Fineline Cube Mar 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...

Company Deals

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Fineline Cube Mar 14, 2024

Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...

Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors

Fineline Cube Mar 14, 2024

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...

Company Deals

BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery

Fineline Cube Mar 14, 2024

BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase I Study of BL-M05D1 in Advanced Solid Tumors

Fineline Cube Mar 14, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has received approval from the National Medical Products...

Company Drug

Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication

Fineline Cube Mar 14, 2024

Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 412 413 414 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.